Strategies, capabilities and activities
No News available
Archive News

In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin

Computational design of antagonist peptides based on the structure of secreted frizzled-related protein-1 (SFRP1) aiming to inhibit Wnt signaling pathway

Methylation of FBN1, SPG20, ITF2, RUNX3, SNCA, MLH1, and SEPT9 genes in circulating cell-free DNA as biomarkers of colorectal cancer

Potential aggregation hot spots in recombinant human keratinocyte growth factor: a computational study

Apoplastic Production of Recombinant AntiVEGF Protein Using Plant-Virus Transient Expression Vector

Effective blocking of neuropilin-1activity using oligoclonal nanobodies targeting different epitopes

Computational assessment of pigment epithelium-derived factor as an anti-cancer protein during its interaction with the receptors

Bacterial production and biophysical characterization of a hard-to-fold scFv against myeloid leukemia cell surface marker, IL-1RAP

Outer membrane vesicles of bordetella pertussis encapsulated into sodium alginate nanoparticles as novel vaccine delivery system

Production of Soluble and Functional Anti-TNF-alpha Fab Fragment in Cytoplasm of E. coli: Investigating the Effect of Process Conditions on Cellular Biomass and Protein Yield Using Response Surface Me

Production of an antibody fragment (Scfv) targeting pcrv protein of pseudomonas aeruginosa in fed-batch cultivation mode

Parvovirus B19 affects thrombopoietin and IL-11 gene expression in human bone marrow mesenchymal stem cells

Investigation of biological activities of two cultivars of Cicer arietinum proteins mass associated with Alzheimers disease

Kallistatin as an inhibitory protein against colorectal cancer cells through binding to LRP6

Targeting of human fibroblast growth factor receptor 2 by a novel specific nanobody

Antibiofilm properties of cathelicidin LL-37: an in-depth review

The chicken chorioallantoic membrane model for isolation of CRISPR/cas9-based HSV-1 mutant expressing tumor suppressor p53

Optimization of the Expression of Recombinant Cetuximab Single-Chain Fragment Variable and Comparative its Purification with Magnetic Nanoparticles and Conventional Fast Protein Liquid Chromatography

Efficient site-specific integration in CHO-K1 cells using CRISPR/Cas9-modified donors

Archive Article
The Medical Biotechnology Group > Recombinant Research Unit

The Recombinant Protein Research Group was the first research group to begin its work on the production, purification, and practical use of recombinant proteins at the Pasteur Institute of Iran.

The first steps began along with the cooperation of important international centers such as the World Health Organization, which was able to provide the group with the basic facilities to achieve this goal. By the entry of PhD students, research began in various fields, including the identification of genes on different strains of leishmaniasis, interferon, and insulin, which provided useful experiences. After the outbreak of HIV in the country and due to the importance of the issue and the need to identify patients genes, the HIV sub-group was established in this group. After preparing the facilities, the identification of the genes of Iranian patients began and over 300 genes were registered in the gene bank. The results showed that in AIDS patients, the source of the virus was contaminated blood from European countries.

The determination of mutations that cause resistance in HIV-positive patients is another research field in the group which plays an important role in determining the patterns of drug use with regard to new strains and mutations in Iranian patients.

The third step in identifying patients at the earliest opportunity was to use Real time PCR technology, which was successfully performed and services were provided to the medical centers. Moreover, with this technique, mutations that cause resistance in HIV-positive patients to drugs were identified, which proved to be very effective in their treatment.

The third goal of the group was to produce HIV detection kit using the technology of recombinant proteins in the country, which its laboratory production begun at the Pasteur Institute of Iran after related studies. Three types of protein are used in this kit, which can detect the presence of HIV infection in the blood sample of individuals. From a global point of view, the production technology of this kit is unique. 3 proteins are produced and purified separately to produce this kit in the world, but a protein in the form of a fusion or compound that contains all three proteins has been used in the Pasteur Institute Kit. Therefore, it has a high sensitivity and the production cost is about one third of the foreign type and it can compete with the foreign type in this respect. In case of production and selling of the kit inside Iran, it can also be exported to other countries, and it is also possible that this kit can be donated to some poor countries in Africa for free, which brings back a good reputation and strengthens the position of Islamic Republic of Iran among these countries.

Home Page | About Us | History | Groups | System Information | Contact Us
Copyright © 2009   BRC All right Reserved Design By Ecomiran